Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02523859
Other study ID # CNS7056-011
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date July 2015
Est. completion date March 2016

Study information

Verified date August 2023
Source Paion UK Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the use of remimazolam as a sedative/hypnotic in general anesthesia. Remimazolam or propofol will be administered together with fentanyl/sufentanil/remifentanil as opioid analgesics and a neuromuscular blocker. In total, 530 patients will be randomized. This group of 530 patients will be split randomly into 2 groups as follows: • 106 patients will be randomized to induction with propofol plus fentanyl or sufentanil or remifentanil and a neuromuscular blocker. Throughout maintenance, the patients will receive propofol and remifentanil until weaning from the mechanical ventilation on the ICU or PACU within 24 hours after induction. Afterwards, sedation with propofol as study medication has to be ended. If necessary, the sedation is to be continued with the hospital's own supplies (propofol or other sedative). • 424 patients will be randomized to induction with remimazolam 6.0 mg/kg/hr together with fentanyl or sufentanil or remifentanil and a neuromuscular blocker. Throughout maintenance, the patients will receive remimazolam and remifentanil until weaning from the mechanical ventilation on the ICU or PACU within 24 hours after induction. The primary endpoint is successful sedation is defined as a Narcotrend index of 60 or less during at least 85% of the maintenance time and no rescue sedative medication administered. The maintenance starts at arrival at the operation theater and ends with the completion of the last skin suture.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Scheduled for major non-emergency cardiac surgery, i.e. surgery assumed to require more than 2 hours of maintenance of general anesthesia and to require the use of extracorporeal circulation, including coronary bypass(es), valve replacement(s), and associated procedures and on-pump minimal invasive surgery 2. Scheduled to receive mechanical ventilation via tracheal intubation (oropharyngeal or nasotracheal) 3. Age at least 18 years 4. Body mass index 18 to =40 kg/m2 5. Willingness and ability to give informed consent, to understand, participate and comply with all study requirements 6. For women of childbearing potential: negative pregnancy test (serum or urine strip) as well as using a highly effective method of birth control. Such methods include: 7. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, with the following routes of administration: oral, intravaginal, transdermal 8. Progestogen-only hormonal contraception associated with inhibition of ovulation, with the following routes of administration: oral, injectable, implantable 9. Intrauterine device 10. Intrauterine hormone-releasing system 11. Bilateral tubal occlusion 12. Sexual abstinence A woman was considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods included hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Exclusion Criteria: 1. Re-do cardiac surgery 2. Surgical procedures that comprised the use of drugs and/or devices that were not approved for marketing 3. Severe tricuspidal insufficiency (III grade) 4. Planned cooling of the patient's body below 32ºC 5. History of or planned stop of circulation, e.g. due to repair of type A dissection of aorta or removal of thrombi from pulmonary artery 6. Planned to receive epidural/spinal anesthesia together with general anesthesia 7. Evidence of uncontrolled hepatic, central nervous system, respiratory, or metabolic dysfunction, or other clinically significant findings at screening that, in the investigator's or medical monitor's opinion, excluded patients from the study 8. Poorly controlled hypertension (e.g. systolic blood pressure =160 mmHg under antihypertensive medication at screening) 9. Patients with severe renal insufficiency or end-stage renal disease (creatinine clearance below 30 mL/min or estimated glomerular filtration rate below 30 mL/min/1.73 m2). Measuring only one of both parameters was sufficient to assess the eligibility of a patient. 10. Patients with clinically uncontrolled coagulation abnormalities, or with coagulation abnormalities not under adequate treatment 11. Patients scheduled for heart or lung transplantation 12. Patients with infectious cardiac disorders (e.g. endocarditis, myocarditis) 13. Patients with sepsis 14. Emergency surgery, status of shock or coma 15. Patients with an ejection fraction from the left ventricle of less than 20% 16. Patients with acute right heart failure 17. Pre-operative use of phosphodiesterase 3 inhibitors 18. Patients with a history of resuscitation 19. Known resistance to benzodiazepines or history of paradoxical effects after administration of benzodiazepines 20. History of hypersensitivity to benzodiazepines, propofol, remifentanil hydrochloride, neuromuscular blockers, flumazenil or other anesthetic agents 21. Use of benzodiazepines within 5 times their half-life or 5 times the half-life of their active metabolites. Exception: Pre-medication with a benzodiazepine according to local standards was allowed. 22. Epilepsy 23. Myasthenia gravis or myasthenic syndrome 24. History of any severe allergy defined as urticaria, angioedema or anaphylaxis 25. Dependence from drugs or history of drug abuse 26. Dependence from alcohol or history of alcohol abuse within the last 5 years 27. Acute alcoholic intoxication or ethanol intake within 48 hours prior to surgery 28. Acute narrow-angle glaucoma 29. Female patients of childbearing potential without acceptable method of birth control (for definitions: see inclusion criterion 6). 30. Pregnant or breast-feeding female patients 31. Patients in receipt of any investigational drug within 30 days or less than 7 half-lives (whichever was longer) before the start of the study, or scheduled to receive one during the study period. 32. Administration of remimazolam in the past 33. Patients unable to communicate with the investigator as required for the study 34. Other reasons that, according to the investigator, excluded the patient from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propofol
Hypnotic drug used for anesthesia
Remimazolam
Benzodiazepine being developed for sedation and anesthesia.

Locations

Country Name City State
Germany Herzzentrum Leipzig GmbH Leipzig

Sponsors (2)

Lead Sponsor Collaborator
Paion UK Ltd. PRA Health Sciences

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success of Procedure A narcotrend index of 60 or less during at least 85% of the maintenance time and no rescue sedative medication administered. During maintenance phase of operation - between arrival at operation theatre and completion of last skin suture (estimated up to 24 hours).
Secondary Hemodynamic stability Expressed as the amount of norepinephrine used. From the start of study medication until completion of the last skin suture (estimated up to 24 hours).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04279054 - Decreased Neuraxial Morphine After Cesarean Delivery Early Phase 1
Active, not recruiting NCT04580030 - Tricuapid Annular Plane Sistolic Excursion Before General Anesthesia Can Predict Hypotension After Induction
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Recruiting NCT04099693 - A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP
Terminated NCT02481999 - Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Recruiting NCT05525104 - The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA op Het Herstel na Anesthesie Bij Kinderen). N/A
Recruiting NCT05024084 - Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth Phase 4
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03277872 - NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope N/A
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Terminated NCT02529696 - Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Terminated NCT03704285 - Development of pk/pd Model of Propofol in Patients With Severe Burns
Recruiting NCT05259787 - EP Intravenous Anesthesia in Hysteroscopy Phase 4
Completed NCT02894996 - Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient? N/A
Completed NCT05386082 - Anesthesia Core Quality Metrics Consensus Delphi Study
Terminated NCT03567928 - Laryngeal Mask in Upper Gastrointestinal Procedures N/A
Recruiting NCT06074471 - Motor Sparing Supraclavicular Block N/A
Completed NCT04163848 - CARbon Impact of aNesthesic Gas